These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

695 related articles for article (PubMed ID: 33965137)

  • 1. Remarks About Retrospective Analysis of Ivermectin Effectiveness on Coronavirus Disease 2019 (ICON Study).
    Ortega-Guillén E; Meneses G; Coila E
    Chest; 2021 May; 159(5):2110-2111. PubMed ID: 33965137
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
    Arouche TDS; Martins AY; Ramalho TC; Júnior RNC; Costa FLP; Filho TSA; Neto AMJC
    J Nanosci Nanotechnol; 2021 Apr; 21(4):2075-2089. PubMed ID: 33500022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. White paper on Ivermectin as a potential therapy for COVID-19.
    Vora A; Arora VK; Behera D; Tripathy SK
    Indian J Tuberc; 2020 Jul; 67(3):448-451. PubMed ID: 32825892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing.
    Jermain B; Hanafin PO; Cao Y; Lifschitz A; Lanusse C; Rao GG
    J Pharm Sci; 2020 Dec; 109(12):3574-3578. PubMed ID: 32891630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Standard Dose Ivermectin for COVID-19.
    Buonfrate D; Bisoffi Z
    Chest; 2021 May; 159(5):2111-2112. PubMed ID: 33965138
    [No Abstract]   [Full Text] [Related]  

  • 6. Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection.
    de Castro CG; Gregianin LJ; Burger JA
    Leuk Lymphoma; 2020 Oct; 61(10):2536-2537. PubMed ID: 32611256
    [No Abstract]   [Full Text] [Related]  

  • 7. Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?
    Jans DA; Wagstaff KM
    Cells; 2020 Sep; 9(9):. PubMed ID: 32942671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A five-day course of ivermectin may reduce the duration of COVID-19 illness.
    Ahmed S; Khan WA
    Int J Infect Dis; 2021 Sep; 110():93-94. PubMed ID: 34325042
    [No Abstract]   [Full Text] [Related]  

  • 9. Ivermectin for COVID-19: Promising but not yet conclusive.
    Van Rensburg R; Decloedt EH; Reuter H; Parker A; Schrueder N; Lahri S
    S Afr Med J; 2021 Jan; 111(3):13187. PubMed ID: 33944732
    [No Abstract]   [Full Text] [Related]  

  • 10. Response.
    Rajter JJ; Rajter JC; Sherman M
    Chest; 2021 May; 159(5):2112-2113. PubMed ID: 33965139
    [No Abstract]   [Full Text] [Related]  

  • 11. Ivermectin for Coronavirus Disease 2019: Yet to Be Well Evaluated Before Clinical Use.
    Hagiya H; Otsuka F
    Clin Ther; 2021 Sep; 43(9):1622-1623. PubMed ID: 34362568
    [No Abstract]   [Full Text] [Related]  

  • 12. A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin.
    Hellwig MD; Maia A
    Int J Antimicrob Agents; 2021 Jan; 57(1):106248. PubMed ID: 33259913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Not Available].
    Meylan P
    Rev Med Suisse; 2021 May; 17(739):1002-1003. PubMed ID: 34009761
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-inflammatory activity of ivermectin in late-stage COVID-19 may reflect activation of systemic glycine receptors.
    DiNicolantonio JJ; Barroso-Aranda J; McCarty MF
    Open Heart; 2021 Apr; 8(1):. PubMed ID: 33875563
    [No Abstract]   [Full Text] [Related]  

  • 15. American College of Medical Toxicology (ACMT) Cautions Against Off-Label Prescribing of Ivermectin for the Prevention or Treatment of COVID-19.
    Calello DP; Kazzi Z; Stolbach A
    J Med Toxicol; 2022 Jan; 18(1):69-70. PubMed ID: 35006547
    [No Abstract]   [Full Text] [Related]  

  • 16. Reactivation of SARS-CoV-2 infection following recovery from COVID-19.
    Chen Z; Xie W; Ge Z; Wang Y; Zhao H; Wang J; Xu Y; Zhang W; Song M; Cui S; Wang X; Pan CQ
    J Infect Public Health; 2021 May; 14(5):620-627. PubMed ID: 33848891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there any prophylactic role for ivermectin in COVID-19-A literature summary.
    Sardana K; Mathachan SR
    J Cosmet Dermatol; 2022 Jan; 21(1):24-26. PubMed ID: 34825774
    [No Abstract]   [Full Text] [Related]  

  • 18. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study.
    Lian N; Xie H; Lin S; Huang J; Zhao J; Lin Q
    Clin Microbiol Infect; 2020 Jul; 26(7):917-921. PubMed ID: 32344167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A chronicle of SARS-CoV-2: Part-I - Epidemiology, diagnosis, prognosis, transmission and treatment.
    Kumar M; Taki K; Gahlot R; Sharma A; Dhangar K
    Sci Total Environ; 2020 Sep; 734():139278. PubMed ID: 32434058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).
    McCullough PA
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32967849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.